Bullfrog AI Holdings Inc
bullfrogai.comWhat Do They Do?
Provides AI-based analysis of biomedical data and develops drug candidates for biopharmaceutical companies and other organizations.
10-K for FY2025, filed Mar 19, 2026We use AI/ML to advance medicines for both internal and external projects. We are committed to increasing the probability of success and…View ↗
Together with our strategic partners and collaborators, our primary goal is to improve the odds of success at any stage of pre-clinical and…View ↗
Our fee for service partnership offering model is designed for biopharmaceutical companies, as well as other organizations of all sizes…View ↗
How Do They Make Money?
Customers pay for biomedical-data analysis in cash, equity, or other consideration; service fees are tied to completed deliverables, while collaborations may add fees tied to milestones.
10-K for FY2025, filed Mar 19, 2026Our fee for service partnership offering model is designed for biopharmaceutical companies, as well as other organizations of all sizes…View ↗
We plan to enter into collaborative arrangements with biotechnology and pharmaceutical companies who have drugs that are in development or…View ↗
The Company anticipates that the majority of its revenues that may be recognized will result from discovery and monetization of new drug…View ↗
During 2025, the Company had a collaboration agreement with a single customer, Eleison Pharmaceuticals, Inc. (“Eleison”), for contract…View ↗
$116.7K
-
10-K for FY2025, filed Mar 19, 2026
$116.7K ↗
Who Are Their Customers?
Biopharmaceutical companies and other organizations engage BullFrog for data analysis; service work is arranged under master services agreements with task orders, while data-use partnerships target mid-size to large biopharma companies.
10-K for FY2025, filed Mar 19, 2026
Do Revenues Turn Into Profits?
No. It lost $6.5M in FY2025.
10-K for FY2025, filed Mar 19, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$1.4MView ↗
- ▼ −5% (Loss)
- vs −$1.4M in Q2 FY2025
-
Mar 30, 2026
Signs drug-target discovery agreement with a global pharmaceutical company
The agreement includes milestone payments and gives the customer an option for exclusive research and development rights to a selected target.
Sources
8-K, filed Mar 30, 2026
On March 27, 2026, BullFrog AI Holdings, Inc. (the “Company”) entered into a Feasibility Agreement (the “Agreement”) with a global…View ↗
Growing. Revenue grew 11.7x in 3 years, from $10K in FY2022 to $116.7K in FY2025, about 127% a year.
From drug rescue to data partnerships
The older report described fee-for-service work and drug rescue as core plans; the latest report also focuses on analyzing proprietary datasets and monetizing resulting drug targets and intellectual property through partnerships.
10-K for FY2022, filed Apr 25, 2023 10-K for FY2025, filed Mar 19, 2026The Company anticipates that the majority of its revenues that may be recognized will result from discovery and monetization of new drug…View ↗
Loading...
